Structure Therapeutics Inc. SEC filings GPCR
Structure Therapeutics Inc. has 271 filings in SEC EDGAR's recent list, going back to Oct 21, 2021. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 8, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
May 7, 2026 | May 7, 2026 |
| 424B5 | Prospectus supplement | May 7, 2026 | — |
| ARS | Annual report to shareholders | Apr 23, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 23, 2026 | Jun 17, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Apr 15, 2026 | Apr 15, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Mar 16, 2026 | Mar 16, 2026 |
| S-8 | Employee stock plan registration | Feb 26, 2026 | — |
| 10-K | Annual report | Feb 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Feb 26, 2026 | Feb 26, 2026 |
| 8-K |
Current report
Material agreement
|
Jan 5, 2026 | Dec 30, 2025 |
| 8-K |
Current report
Other events
|
Dec 10, 2025 | Dec 9, 2025 |
| 424B5 | Prospectus supplement | Dec 10, 2025 | — |
| 424B5 | Prospectus supplement | Dec 8, 2025 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2025 | Dec 8, 2025 |
| 10-Q | Quarterly report | Nov 6, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2025 | Nov 6, 2025 |
| S-3ASR | Automatic shelf registration | Aug 6, 2025 | — |
| 10-Q | Quarterly report | Aug 6, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2025 | Aug 6, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 25, 2025 | Jun 23, 2025 |
| 10-Q | Quarterly report | May 8, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 8, 2025 | May 8, 2025 |
| ARS | Annual report to shareholders | Apr 24, 2025 | Dec 31, 2024 |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 23, 2025 |
| S-8 | Employee stock plan registration | Feb 27, 2025 | — |
| 10-K | Annual report | Feb 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Feb 27, 2025 | Feb 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Dec 17, 2024 | Dec 17, 2024 |
| 10-Q | Quarterly report | Nov 13, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2024 | Nov 13, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure, Other events
|
Sep 17, 2024 | Sep 12, 2024 |
| 8-K |
Current report
Officer or director change
|
Aug 27, 2024 | Aug 24, 2024 |
| 10-Q | Quarterly report | Aug 8, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 8, 2024 | Aug 8, 2024 |
| 8-K |
Current report
Shareholder vote results, Other events
|
Jun 27, 2024 | Jun 25, 2024 |
| 424B4 | Prospectus | Jun 6, 2024 | — |
| EFFECT | Filing | Jun 5, 2024 | — |
| S-1MEF | Filing | Jun 5, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2024 | — |
| CORRESP | Letter to the SEC | Jun 3, 2024 | — |
| CORRESP | Letter to the SEC | Jun 3, 2024 | — |
| 8-K |
Current report
Other events
|
Jun 3, 2024 | Jun 3, 2024 |
| S-1 | Registration statement | Jun 3, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 3, 2024 | Jun 3, 2024 |
| CORRESP | Letter to the SEC | May 31, 2024 | — |
| UPLOAD | Letter from the SEC | May 31, 2024 | — |
| CORRESP | Letter to the SEC | May 24, 2024 | — |
| UPLOAD | Letter from the SEC | May 22, 2024 | — |
| 10-Q | Quarterly report | May 9, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 9, 2024 | May 9, 2024 |
| ARS | Annual report to shareholders | Apr 25, 2024 | Dec 31, 2023 |
| DEF 14A | Proxy statement | Apr 25, 2024 | Jun 25, 2024 |
| S-8 | Employee stock plan registration | Mar 8, 2024 | — |
| 10-K | Annual report | Mar 8, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2024 | Mar 8, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 18, 2023 | Dec 18, 2023 |
| EFFECT | Filing | Nov 29, 2023 | — |
| CORRESP | Letter to the SEC | Nov 27, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 24, 2023 | — |
| DRS | Filing | Nov 20, 2023 | — |
| S-1 | Registration statement | Nov 17, 2023 | — |
| 10-Q | Quarterly report | Nov 17, 2023 | Sep 30, 2023 |
| 10-Q/A | Amended quarterly report | Nov 17, 2023 | Jun 30, 2023 |
| 10-Q/A | Amended quarterly report | Nov 16, 2023 | Jun 30, 2023 |
| NT 10-Q | Filing | Nov 14, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Material agreement, Results of operations
|
Nov 14, 2023 | Nov 7, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Sep 29, 2023 | Sep 29, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 29, 2023 | Sep 29, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 4, 2023 | Aug 3, 2023 |
| 8-K |
Current report
Material agreement
|
Jul 6, 2023 | Jun 29, 2023 |
| 8-K |
Current report
Auditor change
|
Jun 5, 2023 | May 31, 2023 |
| 10-Q | Quarterly report | May 11, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 10-K | Annual report | Mar 30, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2023 | Mar 30, 2023 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Feb 7, 2023 | Feb 7, 2023 |
| S-8 | Employee stock plan registration | Feb 6, 2023 | — |
| 424B4 | Prospectus | Feb 6, 2023 | — |
| SEC STAFF LETTER | Filing | Feb 3, 2023 | — |
| EFFECT | Filing | Feb 2, 2023 | — |
| EFFECT | Filing | Feb 2, 2023 | — |
| S-1MEF | Form s-1mef | Feb 2, 2023 | — |
| CERT | Filing | Feb 2, 2023 | — |
| CORRESP | Letter to the SEC | Jan 31, 2023 | — |
| CORRESP | Letter to the SEC | Jan 31, 2023 | — |
| 8-A12B | Form 8-a12b | Jan 30, 2023 | — |
| S-1/A | Amended registration statement | Jan 30, 2023 | — |
| F-6 | Filing | Jan 30, 2023 | — |
| CORRESP | Letter to the SEC | Jan 23, 2023 | — |
| CORRESP | Letter to the SEC | Jan 12, 2023 | — |
| S-1 | Registration statement | Jan 12, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2023 | — |
| DRS/A | Filing | Dec 6, 2022 | — |
| DRSLTR | Filing | Dec 5, 2022 | — |
| UPLOAD | Letter from the SEC | May 27, 2022 | — |
| DRS/A | Filing | May 13, 2022 | — |
| DRSLTR | Filing | May 12, 2022 | — |
| SEC STAFF LETTER | Filing | Mar 16, 2022 | — |
| UPLOAD | Letter from the SEC | Mar 14, 2022 | — |
| DRS | Filing | Feb 14, 2022 | — |
| D | Filing | Jan 10, 2022 | — |
| D | Filing | Oct 21, 2021 | — |
| D | Filing | Oct 21, 2021 | — |
| D | Filing | Oct 21, 2021 | — |
Showing 112 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GPCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1888886
- Former names
- ShouTi Inc. (until May 13, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.